Literature DB >> 14604668

Design, synthesis and evaluation of a series of novel fumagillin analogues.

Maria Fardis1, Hyung-Jung Pyun, James Tario, Haolun Jin, Choung U Kim, Judy Ruckman, Yun Lin, Louis Green, Brian Hicke.   

Abstract

A series of fumagillin analogues targeted at understanding tolerability of MetAP2 toward substitution at C4 and C6 were synthesized. Initially, the C6 side chain was maintained as cinnamoyl ester and C4 was modified. It was concluded that replacing the natural C4 of fumagillin with a benzyl oxime at C4 resulted in moderate loss of activity toward binding to MetAP2. Placement of a primary or secondary carbamate at C6 did not improve the potency of compounds toward inhibition of MetAP2. However, the inhibitory activity against MetAP2 was gained back by placing polar groups such as piperazinyl carbamate at C6. Small alkyl substituents on the amine of piperazinyl carbamate were well tolerated.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14604668     DOI: 10.1016/j.bmc.2003.08.031

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Early genetic mechanisms underlying the inhibitory effects of endostatin and fumagillin on human endothelial cells.

Authors:  Chiara M Mazzanti; Anita Tandle; Dominique Lorang; Nick Costouros; David Roberts; Generoso Bevilacqua; Steven K Libutti
Journal:  Genome Res       Date:  2004-08       Impact factor: 9.043

2.  Remodelling of the natural product fumagillol employing a reaction discovery approach.

Authors:  Bradley R Balthaser; Meghan C Maloney; Aaron B Beeler; John A Porco; John K Snyder
Journal:  Nat Chem       Date:  2011-12       Impact factor: 24.427

3.  Comprehensive comparison of MetAP2 tissue and cellular expression pattern in lean and obese rodents.

Authors:  Jing Han; Yang Tang; Mingjian Lu; Haiqing Hua
Journal:  Diabetes Metab Syndr Obes       Date:  2018-09-28       Impact factor: 3.168

Review 4.  Research progress in the biological activities of 3,4,5-trimethoxycinnamic acid (TMCA) derivatives.

Authors:  Zefeng Zhao; Huanhuan Song; Jing Xie; Tian Liu; Xue Zhao; Xufei Chen; Xirui He; Shaoping Wu; Yongmin Zhang; Xiaohui Zheng
Journal:  Eur J Med Chem       Date:  2019-04-06       Impact factor: 6.514

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.